


# Nanoscale Advances

Volume 3  
Number 9  
7 May 2021  
Pages 2387–2668

[rsc.li/nanoscale-advances](https://rsc.li/nanoscale-advances)



ISSN 2516-0230

**REVIEW ARTICLE**

James A. Behan, Kenneth A. Dawson *et al.*  
Understanding intracellular nanoparticle trafficking  
fates through spatiotemporally resolved magnetic  
nanoparticle recovery

Cite this: *Nanoscale Adv.*, 2021, 3, 2397

## Understanding intracellular nanoparticle trafficking fates through spatiotemporally resolved magnetic nanoparticle recovery

Emily Sheridan, <sup>†a</sup> Silvia Vercellino, <sup>†ab</sup> Lorenzo Cursi, <sup>a</sup> Laurent Adumeau, <sup>a</sup> James A. Behan <sup>\*a</sup> and Kenneth A. Dawson <sup>\*a</sup>

The field of nanomedicine has the potential to be a game-changer in global health, with possible applications in prevention, diagnostics, and therapeutics. However, despite extensive research focus and funding, the forecasted explosion of novel nanomedicines is yet to materialize. We believe that clinical translation is ultimately hampered by a lack of understanding of how nanoparticles really interact with biological systems. When placed in a biological environment, nanoparticles adsorb a biomolecular layer that defines their biological identity. The challenge for bionanoscience is therefore to understand the evolution of the interactions of the nanoparticle–biomolecules complex as the nanoparticle is trafficked through the intracellular environment. However, to progress on this route, scientists face major challenges associated with isolation of specific intracellular compartments for analysis, complicated by the diversity of trafficking events happening simultaneously and the lack of synchronization between individual events. In this perspective article, we reflect on how magnetic nanoparticles can help to tackle some of these challenges as part of an overall workflow and act as a useful platform to investigate the bionano interactions within the cell that contribute to this nanoscale decision making. We discuss both established and emerging techniques for the magnetic extraction of nanoparticles and how they can potentially be used as tools to study the intracellular journey of nanomaterials inside the cell, and their potential to probe nanoscale decision-making events. We outline the inherent limitations of these techniques when investigating particular bio-nano interactions along with proposed strategies to improve both specificity and resolution. We conclude by describing how the integration of magnetic nanoparticle recovery with sophisticated analysis at the single-particle level could be applied to resolve key questions for this field in the future.

Received 11th December 2020  
Accepted 21st February 2021

DOI: 10.1039/d0na01035a

rsc.li/nanoscale-advances

<sup>a</sup>Centre for BioNano Interactions, School of Chemistry, University College Dublin, Belfield, Dublin 4, Ireland. E-mail: james.behan@cbtni.ucd.ie; Kenneth.a.dawson@cbtni.ucd.ie

<sup>b</sup>UCD Conway Institute of Biomolecular and Biomedical Research, School of Biomolecular and Biomedical Science, University College Dublin, Belfield, Dublin 4, Ireland

<sup>†</sup> Emily Sheridan and Silvia Vercellino contributed equally to this manuscript.



Emily Sheridan obtained her B.A. (Mod.) in Biochemistry from Trinity College Dublin (TCD) in 2017, her research project focusing on novel G-quadruplex binding molecules as anti-cancer therapeutics. Before joining CBNI in 2018, she held research positions in protein crystallography in the Trinity Biomedical Sciences Institute, TCD and molecular cell biology in the Smurfit Institute of Genetics, TCD. She is now

completing her PhD at the Centre for BioNano Interactions (CBNI), UCD with a research focus on the nanoscale molecular recognition that governs the intracellular trafficking of nanoparticles.



Silvia Vercellino obtained her BSc and MSc in Pharmaceutical Chemistry from Università di Torino in 2017. Her project was focused on the synthesis of core-shell magnetic nanoparticles for drug delivery and thermo therapy. She investigated the interaction on nanoparticles and cells at the Centre for BioNano Interactions (CBNI), UCD funded by Erasmus+ program. She is now a PhD student at the Conway Institute of

Biomolecular and Biomedical Research (UCD). Her research aims to isolate and characterize re-engineered nanoparticles and to unravel the biological interaction of complex nanostructures and living systems.



## 1. Introduction

Nanoparticles (NPs) are promising tools for many biomedical applications including diagnostics, drug delivery and as treatment agents.<sup>1–4</sup> An enormous effort has been made to take advantage of the unique features of NPs to enhance drug efficiency by designing and synthesizing a number of delivery systems,<sup>3</sup> with the objective of delivering therapeutics exclusively to the target tissue.<sup>5</sup> However, despite these endeavors and the considerable resources invested, the current state-of-the-art NP-based therapies show a low delivery efficiency,<sup>6</sup> and only a few specific NP-based formulations are currently FDA approved and available on the market.<sup>7</sup>

From the moment of administration, nanomedicine delivery efficiency involves a multitude of complex factors pertaining to *in vivo* transport and biodistribution. One of the most important factors contributing to low delivery efficiency arises from the interaction of NPs with complex biological milieu: it is now

widely accepted that the suspension of NPs in biological fluids results in the formation of an adsorbed layer of biomolecules known as the biomolecular corona.<sup>8</sup> The composition of this corona and the spatial orientation of the biomolecules that comprise it are both critical parameters in the cell-NP recognition process,<sup>9</sup> as particular protein motifs exposed on the surface are recognized by cell membrane receptors.<sup>10</sup> Alterations in the organization of the corona – for example, due to pre-incubation of NPs with different serum concentrations<sup>11</sup> or with specific individual proteins<sup>12</sup> – is known to influence cell uptake.<sup>13</sup> Hence, irrespective of the biological identity imparted to a NP-based therapy through the attachment of targeting ligands or biomolecules, consequent NP internalization depends on the nature of the biomolecular corona formed *in situ*. Moreover, once formed, the composition of the biomolecular corona changes dynamically through constant desorption and adsorption depending on the biomolecular environment encountered as the NP is trafficked through the



*Lorenzo Cursi obtained his BSc in Chemistry and Materials Chemistry and his MSc in Chemistry from the University of Bologna in 2016. His research projects were focused on the development of gravitational field-flow fractionation and the isolation and characterization of magnetosomes through the use of asymmetrical flow field-flow fractionation coupled with multi-angle light scattering*

*(AF4-MALS). He joined the Centre for BioNano Interactions in September 2017 as a PhD student at UCD funded by Celtic Advanced Life Science Innovation Network (CALIN). His research focuses on the development of tools and methods for understanding bionano interactions with a focus on the magnetic toolset.*



*James A. Behan joined the Centre for BioNano Interactions (CBNI), UCD in April 2019 as a Postdoctoral Fellow. Previously he obtained a B.A. (First Class Hons) in Chemistry from Trinity College Dublin (TCD) in 2014 with a Foundation Scholarship. He went on to complete his PhD in Physical Chemistry in TCD in 2018, where his work focused on the preparation of non-crystalline carbon systems*

*with controlled structure and surface chemistry and their application in electrocatalysis and biosensing. In 2020 James won a postdoctoral fellowship from the Irish Research Council for research into the tailoring of nanoparticle surface organization for targeted applications in biology at CBNI.*



*Laurent Adumeau is currently a postdoctoral researcher at the Centre for BioNano Interactions (CBNI), UCD. After completing a MSc in Biochemistry, he obtained his PhD at the University of Bordeaux, with research focusing on the synthesis of inorganic nanoparticles and their controlled surface bio-functionalization for biological applications. Laurent joined Prof. Kenneth Dawson's group at*

*CBNI in 2017. His interdisciplinary research focuses on the investigation of the mechanisms involved in the engineered nanoparticle recognition by cells.*



*Professor Kenneth A. Dawson is both the founding and current Director of the Centre for BioNano Interactions (CBNI) based at University College Dublin (UCD), Ireland. He is also Chair of Physical Chemistry at UCD. The scientific focus of the CBNI is to understand the interaction of nanoparticles with living systems ([www.ucd.ie/cbni](http://www.ucd.ie/cbni)). The Centre seeks to discover those unique architectural and other*

*nanoscale features that control these biological interactions and determine biological outcomes. Professor Dawson is the discoverer of the 'biomolecular corona' effect, for which he was awarded the US National Academy Cozzarelli Prize.*



cell,<sup>8,14,15</sup> which has been shown to result in divergent intracellular sorting outcomes depending on the presence of organelle-specific proteins introduced into the NP-corona.<sup>16</sup> Additionally, since protein exchange kinetics can last hours, the NP corona also retains the memory of the environment to which the NPs have been exposed. This memory is what we will refer to as the 'biomolecular barcode' in this article.

The overwhelming outcome of corona formation for nanomedicine is a lack of both targeting specificity and signaling clarity for the targeted cell. In the majority of cases, this leads to the segregation of NPs after cell uptake within certain cytoplasmic compartments, particularly within the endolysosomal pathway.<sup>17–19</sup> Interestingly, a minor population of NPs do not follow this traditional intracellular route<sup>18</sup> but are instead diverted down alternative trafficking pathways. The initiator of these alternative pathways remains unknown, and the rarity and transient nature of these events make their study challenging, as they are buried in the complexity of the bulk analysis of the cell mechanisms, which can only reveal the dominant routes. Moreover, the *in situ* study of intracellular events is complicated by the difficulty in accessing intracellular compartments.

Magnetic nanoparticles (MNPs) compose a subclass of NPs that is the subject of intense research, in particular within the field of nanomedicine.<sup>20,21</sup> They have properties which are amenable to a variety of applications, such as magnetic resonance imaging (MRI),<sup>22,23</sup> targeted hyper-thermic treatment of tumours,<sup>20,24–28</sup> site-specific-drug delivery and in-cell manipulation through the application of external magnetic fields. However, here we will not focus on applications of MNPs in nanomedicine, but we will instead reflect on how MNPs, once integrated into an overall workflow, can offer a potential platform to elucidate intracellular trafficking events, which is crucial for nanomedicine applications. Indeed, the magnetic nature of MNPs provides the potential to selectively recover the NPs from their intracellular environment<sup>29</sup> to allow a more detailed analysis than is possible with non-magnetic internalized NPs. In principle, by exploiting magnetic extraction at different times in the intracellular trafficking process, it is possible to recover and translate the biomolecular barcode into an understanding of the trafficking lineage of the nanoparticle through multiple intracellular vesicles, unravelling alterations in the corona which redirect the NPs to rarer trafficking pathways.

We believe that applying selective MNP-based extraction techniques will provide the capacity to investigate rare NP trafficking events and understand the mechanisms responsible for divergent NP sorting. This knowledge in turn will enable the development of targeted nanomedicines capable of avoiding the lysosomal pathway. In this article we provide an overview of the application of MNPs in the study of intracellular bionano interactions; we introduce the fundamentals underlying MNP-based extraction as well as emerging technologies that exploit magnetic properties for this purpose. We then describe the challenges inherent to the task of achieving spatiotemporal resolution in the extraction, including issues in the recovery of pure subpopulations and sample contamination, both of which may bias downstream analyses. Finally, we emphasize the need

for single particle analysis in order to deal with the complex heterogeneity of the events happening in the cell. Some low-throughput techniques such as electron microscopy combined with immunostaining already allow for single nanoparticle characterization. However, we argue that a move towards a high throughput and high dimensional analysis workflow at the level of individual extracted NPs will afford the best chance for the field to unravel the precise intracellular bionano interactions governing intracellular trafficking decisions.

## 2. Magnetic isolation of nanoparticles from intracellular compartments

Magnetic separation using commercially available micro- or nanoparticles (the mechanism of which is depicted in Fig. 1a) is one of the most common techniques used in targeted biological extractions<sup>30,31</sup> and has also shown promise in the isolation of cellular organelles.<sup>29</sup> It offers clear advantages *versus* alternative techniques (*e.g.* centrifuge-based techniques), such as the ability to distinguish between organelle sub-populations that share similar buoyancy,<sup>32</sup> no requirement for expensive equipment such as ultracentrifuges, and time efficiency, especially when working with large sample volumes.<sup>33</sup> Magnetic separation can provide samples enriched in specific organelles, such as mitochondria<sup>34</sup> and lysosomes,<sup>29</sup> with good yields and purity, often superior to those provided by centrifuge-based techniques. However, the lack of a standardized procedure for magnetic separation itself and differences in sample processing (*e.g.* lysis procedures) can lead to contradictory results.<sup>34,35</sup> Furthermore, due to the small size of the species involved, the magnetic separation of sub-cellular species requires the use of high magnetic field gradients that can become a source of contamination and mechanical damage, such as vesicle rupture or object compaction (Fig. 1b).<sup>32,35</sup>


Other techniques have been developed for the isolation of organelles, such as fluorescence-assisted organelle sorting (FAOS)<sup>40–42</sup> and free-flow electrophoresis,<sup>43,44</sup> but these lead to high levels of cross contamination.<sup>45</sup> By contrast, magnetic separation techniques, such as immunoprecipitation with magnetic beads, allow for the rapid and targeted isolation of organelles with high purity<sup>45</sup> while remaining fully compatible with downstream analysis.

In short, despite some limitations to which we have just alluded and will discuss in more detail in the following section, magnetic separation currently provides a significant route for the isolation and identification of ultra-rare species in biology, due to its capacity for processing larger volumes of samples and because of its targeting versatility: any species can be targeted for magnetic extraction as long as it can be labelled, internally or externally, with MNPs and other constructs.

### 2.1. Principles of magnetic extraction

Every material possesses magnetic properties, so the term "magnetic nanoparticles" is not in itself a precise definition. Depending mainly on their electronic configuration, a dia- or paramagnetic material will respond weakly to a magnetic field,





**Fig. 1** Magnetic extraction system and limitations. (a) Illustration of the principle of magnetic extraction using a simple bar magnet. MNPs and MNPs with biomolecular corona or internalized within vesicles are selectively attracted toward the magnet by a force (the red vector size is a representation of the magnetic force) in relation to the magnetic field gradient and particles size, as discussed in the main text. (b) Common issues affecting magnetic separation: (i) vesicles/biomolecules not related to the MNP are extracted due to adsorption; (ii) diverse populations with different vesicles/coronas are all extracted simultaneously in bulk, reducing resolution and implying that downstream analysis is invariably an average, and prolonged exposure to large forces at the wall may damage vesicles; (iii) ruptured or damaged vesicles during lysis may not be extracted; (iv) particles may not be captured in the timescale of the experiment depending on their distance from the magnet and their size; and (v) MNPs may pick up or adsorb materials during the extraction process which do not reflect their intracellular trafficking pathway and so the results obtained are misleading. (c) Different magnet geometries showing (i) a quadrupole, (ii) a circular Halbach array generating a hexapole and (iii) combination of different Halbach arrays forming concentric quadrupoles. (d) Schematic representation of FFF separation in normal mode. Parts c (i) and c (ii) of this figure were simulated using Finite Element Method Magnetics<sup>36</sup> based on ref. 37 and 38. Part c (iii) reprinted from O. Baun and P. Blümler, Permanent magnet system to guide superparamagnetic particles, *Journal of Magnetism and Magnetic Materials*, 439, 294–304,<sup>39</sup> Copyright (2017), with permission from Elsevier.

whereas a ferro- or ferrimagnetic material will respond strongly to it. However, it is commonly understood that “magnetic material”, and by extension, “magnetic nanoparticle” refers to the second category, and that is what we refer to in this article. The migration of suspended MNPs and other nanomaterials in a fluid in the presence of a magnetic field is known as magnetophoresis. Here we will restrict our discussion to superparamagnetic materials under typical conditions for the extraction of biological samples such as vesicles, *viz.* MNPs possessing a single magnetic domain, above the blocking temperature. For discussions of paramagnets and other weakly-magnetic materials, the reader is directed to other excellent review articles and monographs on the subject.<sup>46,47</sup>

Under the ascribed conditions, the mobility of a MNP induced by a magnetic field depends on the net magnetic force,  $F_m$ , exerted on the particle which can be approximated as:<sup>48,49</sup>

$$F_m = \frac{V_p}{\mu_0} (\chi_p - \chi_f) (\mathbf{B} \times \nabla) \mathbf{B} \quad (1)$$

where bold type represents vector quantities.  $\mathbf{B}$  is the local magnetic field measured at the particle centre,  $\mu_0$  is the permeability of free space ( $4\pi \times 10^7 \text{ T mA}^{-1}$ ),  $V_p$  is the volume of the particle ( $\text{m}^3$ ), and  $\chi_p$  and  $\chi_f$  refer to the magnetic susceptibility of the nanoparticle and of the surrounding fluid, respectively. The factor  $(\mathbf{B} \times \nabla) \mathbf{B}$  corresponds to the magnetic field intensity and the magnetic gradient employed in the magnetic extraction setup, which may be optimized through the



innovative application of different magnet geometries and organisations, as discussed in the following section. The remaining parameters – particle volume and susceptibility with respect to the medium – are properties of the MNP and the surrounding fluid, forming the basis for MNP separation from non-magnetic milieu and the relative separation of different MNP populations from one another (Fig. 1a). Advancement in the synthesis of magnetic materials means that the size and shape of MNPs can now be easily tuned and NPs can be doped with different metals (Co, Zn *etc.*) to increase their susceptibility.<sup>50–53</sup> However, it is important in the case of *in situ* biological applications to keep in mind the biocompatibility of the materials. Since  $F_m$  as described by eqn (1) depends on both the susceptibilities of the MNP and of the medium, the largest magnetophoretic force can be attained for MNPs with high  $\chi$  values, as is the case for superparamagnetic materials.

The motion of a particle undergoing magnetophoresis within a fluid is opposed by drag forces. Supposing the magnetic particle is spherical, and the fluid flow is laminar, the viscous drag force  $F_d$  experienced is given by the Stokes' law:<sup>54</sup>

$$F_d = 3\pi\eta d_h v_s \quad (2)$$

Here  $\eta$  is the fluid viscosity,  $d_h$  the hydrodynamic diameter of the particle and  $v_s$  the particle's magnetophoretic (terminal) velocity. The MNP may also experience other forces; for instance, for ultrasmall NPs in low magnetic field conditions, Brownian forces may be of significant enough magnitude to invalidate the application of eqn (1), whilst for larger microparticles, gravitational/buoyant forces and flow-induced lift forces will eventually be important enough to compete with or overwhelm magnetic/drag forces.<sup>49,55</sup> Assuming magnetophoretic conditions are such that these forces (and any complex interparticle interactions) may be neglected, an equilibrium between magnetic and drag forces described by eqn (1) and (2) is established, and the magnetophoretic velocity ( $v_s$ ) of the particle can be approximated as:

$$v_s = \frac{d_h^2(\chi_p - \chi_f)(\mathbf{B} \times \nabla)\mathbf{B}}{18\mu_0\eta} \quad (3)$$

Rapid and effective magnetic separation is of particular importance in vesicle extraction because these structures have limited lifetimes in non-physiological conditions and are susceptible to damage from both mechanical and thermal stress. Examining eqn (3), it is clear that the recovery time is inversely proportional to  $v_s$ , and hence to the magnetic field gradient. It is possible to increase the gradient of the magnetic field by assembling several permanent magnets in precise geometries such as quadrupoles,<sup>37,56</sup> Halbach arrays<sup>38,57</sup> and their combinations<sup>39</sup> (Fig. 1c).

Another alternative for increasing the magnetic field exerted by permanent magnets, is by employing columns loaded with beads or wires with a high magnetic permeability that can generate local high magnetic field gradients within the column – so-called 'magnetic chromatography'.<sup>47,58,59</sup> An example of this approach is found in many commercial products such as MACS

separators.<sup>60,61</sup> Different magnet arrangements have been successfully exploited for the separation of magnetically tagged cells,<sup>37,62</sup> viruses,<sup>63</sup> DNA<sup>64,65</sup> and subcellular fractions from cell lysate such as mitochondria,<sup>66</sup> exosomes<sup>67</sup> and endocytic organelles.<sup>29,68</sup>

**2.1.1 Limitations in the magnetic extraction of vesicles with conventional techniques.** The simple approach to magnetic extraction we have described above can be summarized as the magnetophoretic extraction of superparamagnetic particles associated, specifically or otherwise, with the biological sample of interest using large, permanent magnets. This approach has several inherent limitations which must be overcome in order for the technique to be properly applied in studies of intracellular trafficking. Some of these challenges have already been illustrated schematically in Fig. 1b, though we stress that our list is not exhaustive. Contamination is often a problem, especially for subcellular fractions,<sup>35</sup> since during the extraction the magnetic carrier can also 'drag along' undesirable adsorbates. This issue might be solved by iterating the extraction procedure, but this approach lengthens the time required for processing the sample and is not guaranteed to remove such contamination. Considering eqn (3), magnetic recovery requires longer time periods for particles far from the magnet compared to those closer to it. While this aspect could be mitigated through the choice of magnetic geometry and positioning, MNPs are nonetheless present as a distribution of different sizes, and in biological milieu delicate structures composed of loose aggregates of particles or vesicles with numerous internalized MNPs may also exist, all of which will experience different magnitudes of magnetic and drag forces according to differences in surface modification, aggregation state and effective hydrodynamic volume.<sup>69</sup>

As a result, some magnetic species may spend significantly more time accumulated on the wall of the test tube or the surface of a magnetic bead under the influence of a high magnetic gradient, risking damage to biological structures and potential distortion of results due to the aggregation of distinct subpopulations into clusters. Immunoprobe extractions with MNPs may alleviate this issue somewhat, since they typically have specific biological targets which may not be present in sufficiently large concentrations to form significant aggregates. However, even in this more restricted case, magnetic probes will target multiple subpopulations that share common targets. Due to these limitations, magnetic extraction as currently employed is an effective technique for separating magnetic materials from a diamagnetic milieu but lacks discriminatory power between magnetic subpopulations. Such subpopulations may possess extraordinarily divergent biological identities despite apparent similarities in magnetophoretic behaviour, and as such the refinement of the magnetic separation based on characteristics intrinsic to a given population, such as particle size, density, or the presence of specific patterns of receptors, is highly desirable. Despite the limitations just described, magnetic separation techniques are still in many ways superior to centrifugation-based techniques in terms of their selectivity and level of contamination. Moreover, as described in the following section, there are novel techniques for magnetic separation in flow which may help to mitigate these issues.



## 2.2 New techniques exploiting magnetism in extraction

**2.2.1 Magnetic field flow fractionation.** The issues of aggregation and resolution of populations just described are inherent in 'batch' magnetophoresis but may be addressed through the well-established use of continuous flow methods in microfluidic devices.<sup>70–75</sup> While undoubtedly more complex (and therefore more costly) than static magnetic extractions, the approach in principle allows for MNP separation and fractionation as a continuous process amenable to even very small or dilute samples. These systems may easily be coupled to *in situ* detection and analysis techniques downstream, including spectroscopic and light scattering methods, which within the current limits enables subpopulation detection at the distribution level, *i.e.* of fractions consisting of subpopulations with lower polydispersity than the injected sample. The technique – magnetic field flow fractionation (mFFF) is a subclass of field flow fractionation (FFF) (see Fig. 1d), a versatile flow separation technique widely applied in the separation of NPs, macromolecules, and polymers.<sup>71,72,76</sup> The basic principle exploits the laminar, parabolic flow of a fluid suspension in conjunction with a field perpendicular to the direction of flow, to partition NPs by size.

The degree of fractionation can be understood in terms of the retention or accumulation of MNPs, as described by:<sup>70</sup>

$$l = (4d) \left( \frac{k_b T}{\mu \Delta H} \right)^2 \quad (4)$$

Here  $d$  is the particle diameter,  $\mu$  is the magnetic permeability and  $\Delta H$  is the drop off in magnetic field strength across the channel.  $l$  is a parameter that describes the centre of gravity of the particle distribution across the channel (depicted in Fig. 1d). Particles that interact weakly with the applied magnetic field show larger values of  $l$ , which corresponds to shorter retention times. It is clear from eqn (4) that magnetophoresis applied in FFF also separates MNPs on the basis of size, magnetic properties and applied field strength.<sup>70,77</sup> As with magnetic chromatography, non-magnetic particles and surrounding biological materials in the sample milieu are separated from MNPs, as they show no retention in the magnetic field. The principal advantage of FFF is its efficacy in the gentle partitioning of MNP subpopulations in flow, even when starting from a relatively polydisperse colloidal sample. Particle separation may be accomplished on the basis of both differences in particle susceptibility and size, even where these differences are subtle.<sup>78</sup>

However, subpopulations with profound differences in their biological identity will nevertheless exist due to variations in intracellular trafficking history, even among fractionated MNP samples with comparable size and magnetic moment isolated from biological milieu. Identification and isolation of these subpopulations is within the purview of FFF and related techniques.

For non-magnetic NPs, asymmetric FFF (aFFF) and other flow-based techniques have been successfully employed in the gentle, size-based fractionation even of delicate biological samples, such as extracellular vesicles and exomeres.<sup>79</sup> In addition, sedimentation FFF (sFFF), which employs centrifugal forces, introduces density as a variable in NP separation as well as size, allowing for particles with similar size but different

densities to be separated. Here we mention these techniques in the context of 'hyphenation' with mFFF, where two or more of the techniques are run in series. This may be considered as the 'flow' analogue of the combination of different batch techniques, such as centrifugation followed by magnetic extraction, to achieve a higher degree of sample purity. In principle, the hyphenated approach enables a more refined multi-variable subpopulation fractionation on the basis of subtle differences in susceptibility, density, size, and shape. Indeed, hyphenation of asymmetric FFF with single-particle inductively-coupled mass spectrometry (sp-ICPMS) enables subpopulations of metal NPs to be quantified on a particle-by-particle basis. We envision that refined MNP separation by FFF and related techniques may be coupled with downstream analysis techniques, including multiplex epitope mapping (discussed below), allowing quantitative subpopulations identified on the basis of physicochemical parameters to be associated with a particular biological identity.

**2.2.2 Magnetic tweezers.** So far, we have limited the discussion in this article to strategies for bulk extraction of magnetic subpopulations, which are, on the whole, well developed techniques. However, there are few if any established systems that potentially allow for the extraction of single intracellular magnetic particles, even though these would revolutionize the field. To date, the manipulation at the single nanoparticle level has been realized through techniques such as magnetic tweezers, which have been used to study biomechanical forces and bionano interactions (inside cells)<sup>80,81</sup> of magnetic particles after internalization by endocytosis or microinjection into the cytoplasm.<sup>82</sup> The control of a magnetic sub-micrometre sized magnetic bead within a single cell using multipole magnetic tweezers in real time using confocal microscopy has recently been demonstrated,<sup>83</sup> and illustrates the future potential for this toolset in the field of single vesicle manipulation and separation: extremely rare endocytic events could be isolated and analyzed individually.

## 3. Challenges associated with the unravelling of bionano interactions with magnetic nanoparticles

### 3.1 Maintaining the biomolecular integrity of isolated samples

It is important to remember that the purpose of the magnetic separation of the particles from the cell environment is not to collect a material, but to isolate particles associated with individual trafficking events whilst preserving the biomolecular traces associated with their intracellular environment. Hence, disturbances during extraction and isolation steps must be minimized or, when unavoidable, taken into consideration in the analysis of results. Apart from potential mechanical damage incurred during the extraction, most of this interference comes from the inevitable environmental changes happening during the cell lysis or during the extraction itself. Cell lysis induces the release of massive amounts of biomolecules, organelles and cell debris that were previously contained in separate



compartments, all of which have the capacity to adsorb non-specifically onto MNPs or MNP-vesicles of interest. Such interference can be minimized through a two-stage approach: initially, by applying an appropriate cell-lysis technique prior to magnetic extraction, and then following this by careful washing and handling of the sample post-extraction.

Cell lysis procedures for magnetic extraction experiments must reach a balance between incomplete lysis and excessive lysis. Incomplete or partial lysis will leave some intact, whole cells which will be potentially magnetically extracted with the sample of interest. While harsh lysis conditions can induce excessive damage to the lipid membranes of intracellular vesicles, resulting in damage to samples and absorption from surrounding cellular debris. Ideal cell lysis should break only the plasma membrane, releasing the cellular contents untouched and allowing for extraction of intact compartments containing MNPs free from contaminating biomolecules. Time is also an important factor as rapid lysis methods limit damage caused by protease and phosphatase enzymes and changes to the native state of vesicles. Although an old technique, homogenization of osmotically swollen cells remains one of the preferred methods of cell disruption for downstream vesicle analysis as it is gentle, can lyse large volumes rapidly, and requires often standard buffer components and equipment. This technique also presents the strong advantage of avoiding the use of detergents usually used in alternative lysis methods in order to compensate for the need for large mechanical forces to break cells. The use of detergent during the lysis would damage the integrity of vesicle membranes and would also limit downstream analysis.

Following magnetic extraction of nanoparticle-containing compartments, careful washing of samples must be carried out to remove contaminating biomolecules. However, even when care is taken, any approach is liable to result in the loss of weakly interacting partners. Both cell lysis and/or extraction and washing induce a consequent dilution and equilibrium displacement on objects of interest and their interacting partners which can lead to their dissociation. A compromise between sample purity and loss of information must be accepted. Limiting sample damage and losses throughout the steps has heightened importance once dealing with single object analysis. Indeed, while bulk analysis of sample populations can withstand losses and partial damage without jeopardizing the results, with single event analysis even small losses and damage to biomolecules from samples will critically alter the result of the populations based on the result of omics analysis.

Newer microfluidic and lysis-on-a-chip style approaches are being investigated for cell lysis, but the methods employed are often better suited for nucleic acid or protein extraction as they are low throughput, expensive, and challenging to fabricate, and can damage vesicular membranes in the lysis process. Any application would require extensive optimization for subcellular compartment analysis to be reliably achieved.<sup>84</sup> There are potential applications for these emerging techniques downstream of vesicle extraction, for the rupturing of the vesicle membrane for MNP release and subsequent intracellular

corona studies. If incorporated with additional functionalities that could analyse or sort single NPs and vesicles at small volumes, they could become crucial aspects in single NP corona analysis.

### 3.2 Challenges associated with the complex population heterogeneity of intracellular nanoparticles

As we have described in the introduction to this article, the endolysosomal pathway is the dominant trafficking route for MNPs in cells<sup>85</sup> but small subpopulations have been observed to be sorted to other cellular compartments such as the Golgi,<sup>86</sup> and endoplasmic reticulum (ER),<sup>87</sup> or to undergo exocytosis from the cell.<sup>88</sup> The heterogeneity in behavior between individual NPs begins at the plasma membrane, where even single suspensions of NPs are internalized by different uptake processes and at varying rates (Fig. 2a, top panel). This initial disparity within the population is the result of the differences by which the cell 'sees' individual coronas based not only on their biomolecular composition, but also on how the NP is orientated for interaction with cell surface receptors.<sup>11,89</sup> The causes of these phenomena remain largely unknown and unravelling them is a significant challenge for the field, with tremendous potential for exciting breakthroughs if it is overcome. Due to the low frequency of these divergent trafficking events, the tools used to gain a comprehensive insight into intracellular NP interactions must be sensitive enough to both detect and quantify even single events. Such events may first be observed through light microscopy techniques with fluorescently labelled NPs, with further confirmation and exploration accomplished with complementary downstream techniques.

Challenges arise not only in capturing rare, transient events in nanoparticle trafficking but also in our capacity to understand the role of endosomal trafficking vesicle subpopulations in individual trafficking decisions. Imaging approaches are limited by the parameters that can be detected and analyzed at one time, which allows for only few markers available for identifying individual vesicle compartments. It has long been established that endosomal trafficking vesicles are more dynamic than a few surface proteins can reveal, and their "kiss and run" interactions, which result in surface protein and cargo sharing, further complicates their identification.<sup>90,91</sup> Moreover, even in unstimulated cells, intracellular vesicles are highly heterogeneous within the same vesicle subtype,<sup>92</sup> and these subtypes have subtle but significant differences in their functioning.<sup>93</sup> This introduces significant complexity into the analysis and emphasizes the need for extraction and downstream characterisation of single NPS.

The important but often subtle differences within a single class of vesicles (Fig. 2b) can include their size, architecture, motility, spatial localization, functional activity, enzymatic activity and pH. There is an ongoing revolution in our understanding of intracellular vesicles and their range of associated trafficking networks, with slight alterations in functioning already being identified as hallmarks of disease states, highlighting the need to reinvestigate old pathways with a new eye for detail.<sup>94-99</sup> For instance, lysosomes, once considered solely as








Fig. 2 Spatiotemporal heterogeneity and MNP microenvironment. (a) Time resolved recovery of heterogeneous populations can reveal MNP trafficking information. (b) Multi-level complexity of NPs interactions with cells. (c) Cell-free approach towards single-particle analysis.

the degradative arm of the cell, are now known to be far more dynamic and broader-functioning compartments, and play a key role in metabolic sensing for the cell.<sup>100,101</sup> These advances in our understanding are built largely on advanced imaging-based investigations but have been difficult to dissect further due to our inability to isolate and chemically resolve subpopulations in a cell-free environment.<sup>102,103</sup> As discussed previously, isolation of vesicle populations is currently achieved through density-based fractionation or with immunopurification using a limited range of membrane protein markers to define a population, and relying on analysis of these bulk populations results in averaged measurements and a consequent loss of intricacies within samples.

**3.2.1 Spatiotemporal heterogeneity in nanoparticle trafficking.** Considering the diversity among even similar MNPs and their trafficking outcomes, temporal heterogeneity is an intrinsic variable in their dynamic interactions. Furthermore, the pathways followed by the MNPs can be considered as

a sequence of processes that moves them through various compartments, and hence the MNP-vesicle identity must be resolved in a spatiotemporal fashion. To unravel this stepwise trafficking, the experimental approach used is treatment of the cell with the NPs for a very short period (pulse), to allow the NPs to “align on the starting line” on the plasma membrane, with the intent to induce their internalization and trafficking (chase) to occur in parallel. It would then be possible to study every timepoint as a stand-alone scenario and eventually merge the results of each to obtain a time-resolved analysis.<sup>29</sup> In reality, NPs are internalized at different rates and therefore will reach endocytic vesicles at separate times, reducing temporal resolution. Adding to the complexity is that internal trafficking and “sorting” will happen at contrasting times and result in different trafficking “decisions” so that extraction at different time points will result in mixed populations.

The introduction of time-resolved magnetic recovery does allow, however, for enriching of subpopulations of vesicles,



especially those associated with rare intracellular events, and allows for time-resolved investigation of consecutive trafficking “decision-making” steps to help unravel the mechanistic response to biomolecular corona composition. The temporal distribution can be investigated with imaging-based techniques to track over time the intracellular trajectory of single NPs, as a means to identify the critical steps in the trafficking process for extraction times of interest. The need for a multi-dimensional and multi-parametric analysis to investigate the activity and interaction of subcellular structures and NPs is clearly emerging in this field.

## 4. Integrating technology towards single magnetic nanoparticle analysis

From the previous discussion, it is evident that even if the use of MNPs allows for NP recovery from cells (and thus in principle allows for the analysis of NP-related intracellular events), bulk analysis techniques are inherently incapable of identifying effects associated with small sub-populations of NPs and cannot resolve rare events. Indeed, by averaging the overall diversity of events, bulk analysis can only reveal the dominant trafficking and decision-making mechanisms, whilst precious information associated with rare events remains hidden. We believe that to extend further the knowledge that MNPs can bring to in-cell bionano interactions, their use must be supported by a development of single particle analysis techniques (Fig. 2c). Indeed, single MNP analysis is the only way to reliably relate biomolecular identity with ultimate cell fate decisions.

Throughout intracellular trafficking the NP corona will become altered through the addition and loss of biomolecules from the endocytic trafficking vesicles it interacts with<sup>8,16</sup> and will lead to the previously described “biomolecular barcode”. Decoding this barcode requires an understanding of its time-resolved composition of multiple biomolecules. The evolving corona can become a host for multiple bioactive molecules including lipids, and post-translationally modified proteins (for instance differential glycosylation of the corona) resulting in differences in cellular uptake and responses.<sup>104,105</sup> With the large impact of individual biomolecules on the interaction between NPs and cells it is necessary to have an in-depth analysis of the multi-layered identity of individual coronas to fully understand the range of interactions of NPs in cells.

### 4.1 Subcellular and single nanoparticle omics

Omics technologies are increasingly striving for single event analysis, with their limits pushed by the requirement for high-throughput, accurate analysis of low abundance biomolecules. While single cell genomics and transcriptomics are now changing the face of science today, single cell proteomics remains elusive, even if some promising techniques are emerging.<sup>106,107</sup> While we wait for single event analysis to come to fruition, several clever approaches in mass spectrometry (MS) have allowed us to get closer than ever to high resolution subcellular event profiling, with novel methods of analysis of

isotope labelled samples such as LOPIT and SCOPE-MS,<sup>108–111</sup> providing new insights into the complex organelle proteome.

The powerful methodology of these approaches could be applied to temporally resolved fractions of magnetically-extracted vesicles to compare and sample protein distribution throughout the endocytic trafficking pathway of NPs. This would allow an overall view of the biomolecular components of the pathway and, if compared to nanoparticle-depleted fractions, there is the possibility of identifying possible subtypes of vesicles involved in NP trafficking and creating reference “maps” of NP journeys through the cell, a powerful resource in bionano interaction studies.

Performing single-corona proteomics is far more complex than complete single vesicle analysis. Integration of the numerous approaches of advanced downstream analysis with magnetic extraction, under optimal conditions as we have outlined, could aid in identifying single NP biomolecular micro-environments within a complex mixture. Incorporation of analysis of lipidomics, proteomics and post-translational modification states of corona proteins and vesicle carriers will help form the basis of ultramodern NP interactomics.

### 4.2 Quantitative evaluation of the biological identity of recovered magnetic nanoparticles through surface mapping

**4.2.1 Single particle epitope mapping.** Limited access to the biomolecular identity on the surface of single objects of interest can currently be achieved by searching for the presence or absence of specific identified targets using immunolabelling in transmission electron microscopy (TEM) once the MNPs are recovered after their journey through the cell. Commonly used on cell sections, this technique relies on antibodies conjugated to a nanoparticle with a high electron density, such as gold, to create a strong contrast and indicates the position of the molecular target of interest. Recently the principle use of this technique has been to characterize the protein exposition at the surface of nano-objects in a number of relatively simple cases,<sup>9,112</sup> as well as more complex multiplex analysis.<sup>113</sup> By being epitope specific and using monoclonal antibodies as probes, this technique provides information into the surface presentation and accessibility of certain motifs at the nanoparticle surface, as opposed to indicating only their presence. To build a more detailed picture of the NP-corona interface, limited multiplexing can be undertaken by applying identifiable NPs (through size, shape or composition) coupled to immunoprobes with different target epitopes. This in turn will allow for the visualization of the relative location of epitopes and could give information on their potential interactions, which may be important for recognition. However, even if electron microscopy developments tend toward automatic imaging, it is a technique with low throughput due to the time taken per acquisition and the small size of the volume of observation.

**4.2.2 Single event cytometry and building high dimensional lineage maps.** In order to read the diversity of biomolecular barcodes presented by NPs after their recovery from the cell (and thus identify their associated intracellular pathway), it



is important to employ techniques allowing the high throughput reading of multiple markers simultaneously. For cells, the closest analogue of high throughput mapping as we have described is currently achieved using flow cytometry-based technologies, where the potential to discriminate cells between

hundreds of subtypes is facilitated by the addition of multiple fluorescence tags on and within multiple cells.<sup>114</sup> This same approach is being sought and developed for small nano-constructs like exosomes, but traditional cytometers lack the range of resolution required to identify comparatively slight




Fig. 3 Integrated workflow for studying the role of evolving corona in intracellular decision making.



differences between samples. In addition to the low size range required for nanoparticle analysis, the number of fluorescence molecules per object is much lower than is observed in cells and minute differences between samples can be missed. Fluorescence labels are therefore required to have higher brightness in comparison to standard antibody dyes, with quantum dot labelling showing the greatest potential.<sup>115</sup> Non-specific adsorption of antibodies and proteins onto the nanoparticle corona during the labelling process is a major hurdle to achieving reliable results and care must be taken in the design of the labels to minimize their effects. Progress in antibody-derived targeting biomolecules, *e.g.* nanobodies,<sup>116,117</sup> as well as in the selection of high affinity peptides by phage display<sup>118–120</sup> and design of aptamers<sup>121,122</sup> presage a revolution in generalized access to labelling tools with high affinity and specificity for a wide library of targets.

One of the most significant problems in nanoscale event analysis *via* conventional flow cytometers is their fluidic system, which is engineered to hydrodynamically focus cells into single file for their individual analysis and detection within the flow cell, the detection chamber. Flow cytometers, which are mainly in use for immune cell phenotyping and analysis, are typically built with three radius settings based on different standard cell sizes. This means the radius is much greater than the width of organelles or nanoscale vesicles, making it possible for multiple particles to be detected simultaneously as one event. Therefore, flow cytometry experiments require extensive preparation and optimization to prevent coincident events. For this reason, dedicated nano cytometers are being commercialized and fabricated to overcome limitations of current technologies, incorporating flow-based systems for high-throughput analysis of single nanoscale particles.<sup>123</sup> The ultimate achievement of nanoscale cytometry would be the incorporation of nanoscale flow-assisted cell sorting (FACS), or nanoFACS, which could sort identified rare populations for further analysis. Current FACS technology is being employed for use in sorting exosome populations, but its accuracy in sorting is still below the threshold to allow reliable sorting of small particles.<sup>124</sup>

Mass cytometry, often known by its commercial name, cytometry by time of flight (CyTOF), is driving major advances in single-cell profiling, and is beginning to be utilized for single-organelle analysis. It is more powerful than conventional fluorescence cytometry, which is usually limited by dye spectral overlap and detector configuration, as it is based on analysing cell samples with a panel of isotope labelled antibodies, the wide range of potential isotope labels allows for a broader range of simultaneous measurements per sample, from a maximum of approximately 12 labels for fluorescence cytometry up to 40+ with CyTOF.<sup>42,125</sup> Although the hurdle of antibody absorption remains present for experimental design, it provides interesting potential for high-dimensional epitope mapping.

Through identifying compartment specific biomolecules from the surface of extracted coronas, there is the potential to relate back to trafficking steps made by single NPs. This form of “lineage mapping” could be achieved by integrating knowledge acquired in single nanoparticle analysis to read the corona as a biomolecular barcode. This high-dimensional data could then

be processed through dimensionality reduction analyses to create full lineage maps of a nanoparticle population with the potential to create interactome maps for multiple preparations of nanoparticle corona under investigation.<sup>126</sup> Understanding the full range of interactions of introduced nanomedicines is currently the main roadblock towards clinical translation and therefore it is vital to map the full bionano interactome of engineered nanomaterials to cross this clinical barrier.

## 5. Conclusion

The lack of in-depth knowledge of the *in situ* biological interactions of nanostructures has been a major factor hampering both the advancement of the field and nanoscale clinical translation. Through their unique properties, magnetic nanoparticles provide an anchor for researchers for the selective and temporally-resolved recovery of delicate intracellular bio-nanostructures, providing insights into intracellular decision-making events and trafficking pathways. We have outlined the state-of-the-art in magnetic extractions, along with both its key advantages and shortcomings, and have shown how magnetic recovery may be integrated into a workflow combining low-throughput super resolution microscopy with high-throughput omics analysis and nanoparticle surface mapping. This approach in principle enables the quantitative association of the molecular barcode of trafficked nanoparticles with key biological decision-making events (Fig. 3). This knowledge will have profound implications for the design of novel targeted nanomedicines. While the technological, instrumental, and methodological developments are progressing, there is now an interesting opportunity (and need) for a much deeper and stronger connection between those developments, and the key bionanoscience questions: in this regard, we have emphasized the need for analysis to be refined to the level of single cellular sub-compartments, narrow populations of intracellular nanoparticles, and ultimately single-particle analysis, if the field is to truly advance. The combination of teams of scientists that are able to bring the relevant concepts, skills, and infrastructure together to develop our understanding of mechanisms could now significantly affect the pace of overall development of nanoscale biomedical research and translation. This represents a significant opportunity for those in relevant communities.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

KAD, LA, ES and SV acknowledge that this publication has emanated from research supported in part by grants from Science Foundation Ireland [17/NSFC/4898 (KAD, LA and ES), 17/ERC/D/4962 (KAD) and 15/SIRG/3423 (SV)]. LC acknowledges this work was part-funded by the Celtic Advanced Life Science Innovation Network (CALIN), an EU INTERREG project part-funded by Welsh government through the Ireland-Wales Programme. SV also acknowledges support by the PhD Research Scholarship from the UCD School of Biomolecular and



Biomedical Science. JAB acknowledges the support of the Irish Research Council under Grant Number GOIPD/2020/434. Fig. 2c and the TOC were created with BioRender.com.

## References

- G. Chen, I. Roy, C. Yang and P. N. Prasad, *Chem. Rev.*, 2016, **116**, 2826–2885.
- J. Yoo, C. Park, G. Yi, D. Lee and H. Koo, *Cancers*, 2019, **11**, 640.
- E. Blanco, H. Shen and M. Ferrari, *Nat. Biotechnol.*, 2015, **33**, 941.
- R. Tietze, J. Zaloga, H. Unterweger, S. Lyer, R. P. Friedrich, C. Janko, M. Pöttler, S. Dürr and C. Alexiou, *Biochem. Biophys. Res. Commun.*, 2015, **468**, 463–470.
- J. S. Suk, Q. Xu, N. Kim, J. Hanes and L. M. Ensign, *Adv. Drug Delivery Rev.*, 2016, **99**, 28–51.
- S. Wilhelm, A. J. Tavares, Q. Dai, S. Ohta, J. Audet, H. F. Dvorak and W. C. Chan, *Nat. Rev. Mater.*, 2016, **1**, 16014.
- D. Bobo, K. J. Robinson, J. Islam, K. J. Thurecht and S. R. Corrie, *Pharm. Res.*, 2016, **33**, 2373.
- M. P. Monopoli, C. Aberg, A. Salvati and K. A. Dawson, *Nat. Nanotechnol.*, 2012, **7**, 779–786.
- P. M. Kelly, C. Åberg, E. Polo, A. O'Connell, J. Cookman, J. Fallon, Ž. Krpetić and K. A. Dawson, *Nat. Nanotechnol.*, 2015, **10**, 472.
- S. Lara, F. Alnasser, E. Polo, D. Garry, M. C. Lo Giudice, D. R. Hristov, L. Rocks, A. Salvati, Y. Yan and K. A. Dawson, *ACS Nano*, 2017, **11**, 1884–1893.
- V. Francia, K. Yang, S. Deville, C. Reker-Smit, I. Nelissen and A. Salvati, *ACS Nano*, 2019, **13**, 11107–11121.
- S. Ritz, S. Schöttler, N. Kotman, G. Baier, A. Musyanovych, J. Kuharev, K. Landfester, H. Schild, O. Jahn, S. Tenzer and V. Mailänder, *Biomacromolecules*, 2015, **16**, 1311–1321.
- Y. Zhang, J. L. Y. Wu, J. Lazarovits and W. C. W. Chan, *J. Am. Chem. Soc.*, 2020, **142**, 8827–8836.
- T. Cedervall, I. Lynch, S. Lindman, T. Berggård, E. Thulin, H. Nilsson, K. A. Dawson and S. Linse, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 2050–2055.
- H. Mohammad-Beigi, Y. Hayashi, C. M. Zeuthen, H. Eskandari, C. Scavenius, K. Juul-Madsen, T. Vorup-Jensen, J. J. Enghild and D. S. Sutherland, *Nat. Commun.*, 2020, **11**, 4535.
- M. Qin, J. Zhang, M. Li, D. Yang, D. Liu, S. Song, J. Fu, H. Zhang, W. Dai, X. Wang, Y. Wang, B. He and Q. Zhang, *Theranostics*, 2020, **10**, 1213–1229.
- S. Barua and S. Mitragotri, *Nano Today*, 2014, **9**, 223–243.
- P. Sandin, L. W. Fitzpatrick, J. C. Simpson and K. A. Dawson, *ACS Nano*, 2012, **6**, 1513–1521.
- P. Foroozandeh and A. A. Aziz, *Nanoscale Res. Lett.*, 2018, **13**, 339.
- A. K. Gupta and M. Gupta, *Biomaterials*, 2005, **26**, 3995–4021.
- Q. A. Pankhurst, N. T. K. Thanh, S. K. Jones and J. Dobson, *J. Phys. D: Appl. Phys.*, 2009, **42**, 224001.
- J. Reguera, D. Jiménez de Aberasturi, M. Henriksen-Lacey, J. Langer, A. Espinosa, B. Szczupak, C. Wilhelm and L. M. Liz-Marzán, *Nanoscale*, 2017, **9**, 9467–9480.
- C. Sun, J. S. H. Lee and M. Zhang, *Adv. Drug Delivery Rev.*, 2008, **60**, 1252–1265.
- A. Espinosa, J. Reguera, A. Curcio, Á. Muñoz-Noval, C. Kuttner, A. Van de Walle, L. M. Liz-Marzán and C. Wilhelm, *Small*, 2020, **16**, 1904960.
- F. Gazeau, M. Lévy and C. Wilhelm, *Nanomedicine*, 2008, **3**, 831–844.
- R. Di Corato, A. Espinosa, L. Lartigue, M. Tharaud, S. Chat, T. Pellegrino, C. Ménager, F. Gazeau and C. Wilhelm, *Biomaterials*, 2014, **35**, 6400–6411.
- Z. Nemati, J. Alonso, I. Rodrigo, R. Das, E. Garaio, J. A. Garcia, I. Orue, M.-H. Phan and H. Srikanth, *J. Phys. Chem. C*, 2018, **122**, 2367.
- F. M. Kievit and M. Zhang, *Acc. Chem. Res.*, 2011, **44**, 853–862.
- F. Bertoli, G.-L. Davies, M. P. Monopoli, M. Moloney, Y. K. Gun'ko, A. Salvati and K. A. Dawson, *Small*, 2014, **10**, 3307–3315.
- I. Šafařík and M. Šafaříková, *J. Chromatogr. B: Biomed. Sci. Appl.*, 1999, **722**, 33–53.
- A. A. Neurauder, M. Bonyhadi, E. Lien, L. Nøkleby, E. Ruud, S. Camacho and T. Aarvak, in *Cell separation*, Springer, 2007, pp. 41–73.
- J. Fritsch, V. Tchikov, L. Hennig, R. Lucius and S. Schütze, *Traffic*, 2019, **20**, 246–258.
- W. W. Chen, E. Freinkman and D. M. Sabatini, *Nat. Protoc.*, 2017, **12**, 2215–2231.
- H. T. Hornig-Do, G. Gunther, M. Bust, P. Lehnartz, A. Bosio and R. J. Wiesner, *Anal. Biochem.*, 2009, **389**, 1–5.
- L. Kappler, J. Li, H. U. Haring, C. Weigert, R. Lehmann, G. Xu and M. Hoene, *Sci. Rep.*, 2016, **6**, 21107.
- D. C. Meeker, *Finite Element Method Magnetics*, 2018, <http://www.femm.info/wiki/HomePage>, (accessed December 2020).
- M. Zborowski and J. J. Chalmers, *Anal. Chem.*, 2011, **83**, 8050–8056.
- P. Joshi, P. S. Williams, L. R. Moore, T. Caralla, C. Boehm, G. Muschler and M. Zborowski, *Anal. Chem.*, 2015, **87**, 9908–9915.
- O. Baun and P. Blümmler, *J. Magn. Magn. Mater.*, 2017, **439**, 294–304.
- D. J. Gauthier, J. A. Sobota, F. Ferraro, R. E. Mains and C. Lazure, *Proteomics*, 2008, **8**, 3848–3861.
- M. Degtyarev, M. Reichelt and K. Lin, *PLoS One*, 2014, **9**, e87707.
- H. M. G. Brown and E. A. Arriaga, *Anal. Chem.*, 2018, **90**, 13315–13321.
- R. Wildgruber, G. Weber, P. Wise, D. Grimm and J. Bauer, *Proteomics*, 2014, **14**, 629–636.
- M. Islinger, R. Wildgruber and A. Volkl, *Electrophoresis*, 2018, **39**, 2288–2299.
- A. K. Tharkeshwar, K. Gevaert and W. Annaert, *Proteomics*, 2018, **18**, e1700113.



- 46 J. G. Webster, M. Zborowski and J. J. Chalmers, in *Wiley Encyclopedia of Electrical and Electronics Engineering*, 2015, pp. 1–23, DOI: 10.1002/047134608x.W8236.
- 47 L. Borlido, A. M. Azevedo, A. C. Roque and M. R. Aires-Barros, *Biotechnol. Adv.*, 2013, **31**, 1374–1385.
- 48 X. Xuan, *Micromachines*, 2019, **10**, 744.
- 49 M. Hejazian, W. Li and N. T. Nguyen, *Lab Chip*, 2015, **15**, 959–970.
- 50 L. M. Bronstein, X. Huang, J. Retrum, A. Schmucker, M. Pink, B. D. Stein and B. Draznea, *Chem. Mater.*, 2007, **19**, 3624–3632.
- 51 J. T. Jang, H. Nah, J. H. Lee, S. H. Moon, M. G. Kim and J. Cheon, *Angew. Chem., Int. Ed.*, 2009, **48**, 1234–1238.
- 52 S. Kralj and D. Makovec, *ACS Nano*, 2015, **9**, 9700–9707.
- 53 J. Park, K. An, Y. Hwang, J.-G. Park, H.-J. Noh, J.-Y. Kim, J.-H. Park, N.-M. Hwang and T. Hyeon, *Nat. Mater.*, 2004, **3**, 891–895.
- 54 J. Lunacek, M. Lesnak, P. Jandacka, R. Dvorsky, J. Repkova, J. Seidlerova and N. Vitkovska, *Sep. Sci. Technol.*, 2015, **50**, 2606–2615.
- 55 J. S. Park, S. H. Song and H. I. Jung, *Lab Chip*, 2009, **9**, 939–948.
- 56 H. Felice, G. Ambrosio, M. Anerella, R. Bossert, S. Caspi, D. W. Cheng, D. R. Dietderich, P. Ferracin, A. K. Ghosh, R. Hafalia, C. R. Hannaford, V. Kashikhin, J. Schmalze, S. Prestemon, G. L. Sabbi, P. Wanderer and A. V. Zlobin, *IEEE Trans. Appl. Supercond.*, 2009, **19**, 1235–1239.
- 57 J. E. Hilton and S. M. McMurtry, *J. Magn. Magn. Mater.*, 2012, **324**, 2051–2056.
- 58 A. Ditsch, S. Lindenmann, P. E. Laibinis, D. I. C. Wang and T. A. Hatton, *Ind. Eng. Chem. Res.*, 2005, **44**, 6824–6836.
- 59 G. D. Moeser, K. A. Roach, W. H. Green, T. Alan Hatton and P. E. Laibinis, *AIChE J.*, 2004, **50**, 2835–2848.
- 60 C. V. Mura, M. I. Becker, A. Orellana and D. Wolff, *J. Immunol. Methods*, 2002, **260**, 263–271.
- 61 M. Lewin, N. Carlesso, C.-H. Tung, X.-W. Tang, D. Cory, D. T. Scadden and R. Weissleder, *Nat. Biotechnol.*, 2000, **18**, 410–414.
- 62 R. Hanamsagar, T. Reizis, M. Chamberlain, R. Marcus, F. O. Nestle, E. de Rinaldis and V. Savova, *Sci. Rep.*, 2020, **10**, 2219.
- 63 C. Wang, C. Wang, X. Wang, K. Wang, Y. Zhu, Z. Rong, W. Wang, R. Xiao and S. Wang, *ACS Appl. Mater. Interfaces*, 2019, **11**, 19495–19505.
- 64 J. H. Min, M. K. Woo, H. Y. Yoon, J. W. Jang, J. H. Wu, C. S. Lim and Y. K. Kim, *Anal. Biochem.*, 2014, **447**, 114–118.
- 65 S. Ghahari, S. Ghahari and G. A. Nematzadeh, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2018, **1102–1103**, 125–134.
- 66 B. Banik and S. Dhar, *Curr. Protoc. Cell Biol.*, 2017, **76**, 25.24.21–25.24.20.
- 67 S. Zong, L. Wang, C. Chen, J. Lu, D. Zhu, Y. Zhang, Z. Wang and Y. Cui, *Anal. Methods*, 2016, **8**, 5001–5008.
- 68 A. K. Tharkeshwar, J. Trekker, W. Vermeire, J. Pauwels, R. Sannerud, D. A. Priestman, D. Te Vrucchte, K. Vints, P. Baatsen, J. P. Decuyper, H. Lu, S. Martin, P. Vangheluwe, J. V. Swinnen, L. Lagae, F. Impens, F. M. Platt, K. Gevaert and W. Annaert, *Sci. Rep.*, 2017, **7**, 41408.
- 69 S. P. Yeap, S. S. Leong, A. L. Ahmad, B. S. Ooi and J. Lim, *J. Phys. Chem. C*, 2014, **118**, 24042–24054.
- 70 T. M. Vickrey and J. A. Garcia-ramirez, *Sep. Sci. Technol.*, 1980, **15**, 1297–1304.
- 71 H. Kato, in *Characterization of Nanoparticles*, ed. V.-D. Hodoroaba, W. E. S. Unger and A. G. Shard, Elsevier, 2020, pp. 249–264, DOI: 10.1016/b978-0-12-814182-3.00016-x.
- 72 C. Contado, *Anal. Bioanal. Chem.*, 2017, **409**, 2501–2518.
- 73 F. Del Giudice, H. Madadi, M. M. Villone, G. D'Avino, A. M. Cusano, R. Vecchione, M. Ventre, P. L. Maffettone and P. A. Netti, *Lab Chip*, 2015, **15**, 1912–1922.
- 74 G. D. Chen, C. J. Alberts, W. Rodriguez and M. Toner, *Anal. Chem.*, 2010, **82**, 723–728.
- 75 N. Pamme, *Lab Chip*, 2006, **6**, 24–38.
- 76 T. Salafi, K. K. Zeming and Y. Zhang, *Lab Chip*, 2017, **17**, 11–33.
- 77 T. C. Schunk, J. Gorse and M. F. Burke, *Sep. Sci. Technol.*, 1984, **19**, 653–666.
- 78 A. H. Latham, R. S. Freitas, P. Schiffer and M. E. Williams, *Anal. Chem.*, 2005, **77**, 5055–5062.
- 79 H. Zhang, D. Freitas, H. S. Kim, K. Fabijanic, Z. Li, H. Chen, M. T. Mark, H. Molina, A. B. Martin, L. Bojmar, J. Fang, S. Rampersaud, A. Hoshino, I. Matei, C. M. Kenific, M. Nakajima, A. P. Mutvei, P. Sansone, W. Buehring, H. Wang, J. P. Jimenez, L. Cohen-Gould, N. Paknejad, M. Brendel, K. Manova-Todorova, A. Magalhães, J. A. Ferreira, H. Osório, A. M. Silva, A. Massey, J. R. Cubillos-Ruiz, G. Galletti, P. Giannakakou, A. M. Cuervo, J. Blenis, R. Schwartz, M. S. Brady, H. Peinado, J. Bromberg, H. Matsui, C. A. Reis and D. Lyden, *Nat. Cell Biol.*, 2018, **20**, 332–343.
- 80 Q. Feng, S. S. Lee and B. Kornmann, *Micromachines*, 2019, **10**, 538.
- 81 J. Lim, C. Lanni, E. R. Everts, F. Lanni, R. D. Tilton and S. A. Majetich, *ACS Nano*, 2011, **5**, 217–226.
- 82 F. Etoc, D. Lisse, Y. Bellaiche, J. Piehler, M. Coppey and M. Dahan, *Nat. Nanotechnol.*, 2013, **8**, 193–198.
- 83 X. Wang, C. Ho, Y. Tsatskis, J. Law, Z. Zhang, M. Zhu, C. Dai, F. Wang, M. Tan, S. Hopyan, H. McNeill and Y. Sun, *Sci. Robot.*, 2019, **4**, eaav6180.
- 84 M. Shehadul Islam, A. Aryasomayajula and P. R. Selvaganapathy, *Micromachines*, 2017, **8**, 83.
- 85 S. Behzadi, V. Serpooshan, W. Tao, M. A. Hamaly, M. Y. Alkawareek, E. C. Dreaden, D. Brown, A. M. Alkilany, O. C. Farokhzad and M. Mahmoudi, *Chem. Soc. Rev.*, 2017, **46**, 4218–4244.
- 86 A. Paillard, F. Hindré, C. Vignes-Colombeix, J.-P. Benoit and E. Garcion, *Biomaterials*, 2010, **31**, 7542–7554.
- 87 Y. Cui, W. Shan, R. Zhou, M. Liu, L. Wu, Q. Guo, Y. Zheng, J. Wu and Y. Huang, *Nanoscale*, 2018, **10**, 1494–1507.
- 88 T. Yong, X. Zhang, N. Bie, H. Zhang, X. Zhang, F. Li, A. Hakeem, J. Hu, L. Gan and H. A. Santos, *Nat. Commun.*, 2019, **10**, 1–16.



- 89 C. C. Fleischer and C. K. Payne, *J. Phys. Chem. B*, 2014, **118**, 14017–14026.
- 90 A. Gupta, F. Rivera-Molina, Z. Xi, D. Toomre and A. Schepartz, *Nat. Chem. Biol.*, 2020, **16**, 408–414.
- 91 J. Klumperman and G. Raposo, *Cold Spring Harbor Perspect. Biol.*, 2014, **6**, a016857.
- 92 H. Wu, P. Carvalho and G. K. Voeltz, *Science*, 2018, **361**, eaan5835.
- 93 N. Naslavsky and S. Caplan, *J. Cell Sci.*, 2018, **131**, jcs216499.
- 94 R. Willett, J. A. Martina, J. P. Zewe, R. Wills, G. R. V. Hammond and R. Puertollano, *Nat. Commun.*, 2017, **8**, 1580.
- 95 J. C. Stinchcombe, E. Majorovits, G. Bossi, S. Fuller and G. M. Griffiths, *Nature*, 2006, **443**, 462–465.
- 96 J. S. Bonifacino and J. Neefjes, *Curr. Opin. Cell Biol.*, 2017, **47**, 1–8.
- 97 J. Neefjes, M. M. L. Jongasma and I. Berlin, *Trends Cell Biol.*, 2017, **27**, 580–594.
- 98 D. Dong, X. Huang, L. Li, H. Mao, Y. Mo, G. Zhang, Z. Zhang, J. Shen, W. Liu, Z. Wu, G. Liu, Y. Liu, H. Yang, Q. Gong, K. Shi and L. Chen, *Light: Sci. Appl.*, 2020, **9**, 11.
- 99 R. Sannerud, C. Esselens, P. Ejsmont, R. Mattera, L. Rochin, A. K. Tharkeshwar, G. De Baets, V. De Wever, R. Habets, V. Baert, W. Vermeire, C. Michiels, A. J. Groot, R. Wouters, K. Dillen, K. Vints, P. Baatsen, S. Munck, R. Derua, E. Waelkens, G. S. Basi, M. Mercken, M. Vooijs, M. Bollen, J. Schymkowitz, F. Rousseau, J. S. Bonifacino, G. Van Niel, B. De Strooper and W. Annaert, *Cell*, 2016, **166**, 193–208.
- 100 R. E. Lawrence and R. Zoncu, *Nat. Cell Biol.*, 2019, **21**, 133–142.
- 101 K. Dan, A. T. Veetil, K. Chakraborty and Y. Krishnan, *Nat. Nanotechnol.*, 2019, **14**, 252–259.
- 102 K. Leung, K. Chakraborty, A. Saminathan and Y. Krishnan, *Nat. Nanotechnol.*, 2019, **14**, 176–183.
- 103 A. M. Valm, S. Cohen, W. R. Legant, J. Melunis, U. Hershberg, E. Wait, A. R. Cohen, M. W. Davidson, E. Betzig and J. Lippincott-Schwartz, *Nature*, 2017, **546**, 162–167.
- 104 S. Wan, P. M. Kelly, E. Mahon, H. Stockmann, P. M. Rudd, F. Caruso, K. A. Dawson, Y. Yan and M. P. Monopoli, *ACS Nano*, 2015, **9**, 2157–2166.
- 105 F. Bertoli, D. Garry, M. P. Monopoli, A. Salvati and K. A. Dawson, *ACS Nano*, 2016, **10**, 10471–10479.
- 106 N. Slavov, *Science*, 2020, **367**, 512.
- 107 B. Budnik, E. Levy, G. Harmange and N. Slavov, *Genome Biol.*, 2018, **19**, 161.
- 108 E. Lundberg and G. H. H. Borner, *Nat. Rev. Mol. Cell Biol.*, 2019, **20**, 285–302.
- 109 A. Geladaki, N. Kočevar Britovšek, L. M. Breckels, T. S. Smith, O. L. Vennard, C. M. Mulvey, O. M. Crook, L. Gatto and K. S. Lilley, *Nat. Commun.*, 2019, **10**, 331.
- 110 L. J. Foster, C. L. de Hoog, Y. Zhang, Y. Zhang, X. Xie, V. K. Mootha and M. Mann, *Cell*, 2006, **125**, 187–199.
- 111 T. P. Dunkley, R. Watson, J. L. Griffin, P. Dupree and K. S. Lilley, *Mol. Cell. Proteomics*, 2004, **3**, 1128–1134.
- 112 L. M. Herda, D. R. Hristov, M. C. Lo Giudice, E. Polo and K. A. Dawson, *J. Am. Chem. Soc.*, 2017, **139**, 111–114.
- 113 N. Arraud, R. Linares, S. Tan, C. Gounou, J.-M. Pasquet, S. Mornet and A. R. Brisson, *J. Thromb. Haemostasis*, 2014, **12**, 614–627.
- 114 S. P. Perfetto, P. K. Chattopadhyay and M. Roederer, *Nat. Rev. Immunol.*, 2004, **4**, 648–655.
- 115 M. C. Lo Giudice, L. M. Herda, E. Polo and K. A. Dawson, *Nat. Commun.*, 2016, **7**, 13475.
- 116 P. Holliger and P. J. Hudson, *Nat. Biotechnol.*, 2005, **23**, 1126–1136.
- 117 S. Muyldermans, *Annu. Rev. Biochem.*, 2013, **82**, 775–797.
- 118 G. P. Smith, *Science*, 1985, **228**, 1315–1317.
- 119 R. H. Hoess, *Chem. Rev.*, 2001, **101**, 3205–3218.
- 120 S. L. Deutscher, *Chem. Rev.*, 2010, **110**, 3196–3211.
- 121 R. Stoltenburg, C. Reinemann and B. Strehlitz, *Biomol. Eng.*, 2007, **24**, 381–403.
- 122 S. Tombelli, M. Minunni and M. Mascini, *Biosens. Bioelectron.*, 2005, **20**, 2424–2434.
- 123 H. Lian, S. He, C. Chen and X. Yan, *Annu. Rev. Anal. Chem.*, 2019, **12**, 389–409.
- 124 A. Morales-Kastresana, T. A. Musich, J. A. Welsh, W. Telford, T. Demberg, J. C. S. Wood, M. Bigos, C. D. Ross, A. Kachynski, A. Dean, E. J. Felton, J. Van Dyke, J. Tigges, V. Toxavidis, D. R. Parks, W. R. Overton, A. H. Kesarwala, G. J. Freeman, A. Rosner, S. P. Perfetto, L. Pasquet, M. Terabe, K. McKinnon, V. Kapoor, J. B. Trepel, A. Puri, H. Kobayashi, B. Yung, X. Chen, P. Guion, P. Choyke, S. J. Knox, I. Ghiran, M. Robert-Guroff, J. A. Berzofsky and J. C. Jones, *J. Extracell. Vesicles*, 2019, **8**, 1597603.
- 125 R. Gadalla, B. Noamani, B. L. MacLeod, R. J. Dickson, M. Guo, W. Xu, S. Lukhele, H. J. Elsaesser, A. R. A. Razak, N. Hirano, T. L. McGaha, B. Wang, M. Butler, C. J. Guidos, P. S. Ohashi, L. L. Siu and D. G. Brooks, *Front. Radiat. Oncol.*, 2019, **9**, DOI: 10.3389/fonc.2019.00415.
- 126 S. Palit, C. Heuser, G. P. de Almeida, F. J. Theis and C. E. Zielinski, *Front. Immunol.*, 2019, **10**, DOI: 10.3389/fimmu.2019.01515.

